Advanced Biomed Inc. Common Stock (ADVB)vsAstraZeneca PLC (AZN)
ADVB
Advanced Biomed Inc. Common Stock
$2.64
-11.41%
HEALTHCARE · Cap: $6.58M
AZN
AstraZeneca PLC
$169.51
+2.88%
HEALTHCARE · Cap: $263.78B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 48077307% more annual revenue ($61.37B vs $127,640). ADVB leads profitability with a 5231.0% profit margin vs 17.0%. AZN earns a higher WallStSmart Score of 62/100 (C+).
ADVB
Avoid30
out of 100
Grade: F
AZN
Buy62
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ADVB.
Margin of Safety
+13.1%
Fair Value
$194.96
Current Price
$169.51
$25.45 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Keeps 5231 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
Moderate valuation
2.5% earnings growth
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ADVB
The strongest argument for ADVB centers on Price/Book, Profit Margin, Debt/Equity. Profitability is solid with margins at 5231.0% and operating margin at -3856.0%.
Bull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.22 suggests the stock is reasonably priced for its growth.
Bear Case : ADVB
The primary concerns for ADVB are Revenue Growth, EPS Growth, Market Cap.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, EPS Growth, Altman Z-Score.
Key Dynamics to Monitor
ADVB profiles as a value stock while AZN is a mature play — different risk/reward profiles.
AZN is growing revenue faster at 6.4% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.
Bottom Line
AZN scores higher overall (62/100 vs 30/100), backed by strong 17.0% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Advanced Biomed Inc. Common Stock
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Advanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies and provides them for precision oncology detection, diagnosis, and treatment in Taiwan. The company is headquartered in New York, New York.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?